Immune cells Tailor-Made to attack pancreatic cancer enter first human test
Disease control
Not yet recruiting
This early-stage trial tests a new therapy called MT-601, which uses a patient's own immune T-cells trained to recognize multiple cancer-related targets. It is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study will check safety …
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC